Eeftinck Schattenkerk J K, Danner S A, Lange J M, Paul D A, van Boxtel C J, Miedema F, Schellekens P T, Goudsmit J
Department of Internal Medicine, University of Amsterdam.
Arch Intern Med. 1988 Jan;148(1):209-11.
Ten homosexual men with the acquired immunodeficiency syndrome were included in a serologic follow-up study (duration, 40 weeks) of human immunodeficiency virus (HIV) antigenemia. Five of these men were treated with the reverse transcriptase inhibitor, suramin, for a period of 19 to 37 weeks. In contrast with reported changes in HIV antigen levels after treatment with zidovudine, HIV antigenemia persisted in the suramin-treated group, as well as in the untreated group. No clinical or immunologic improvement was seen in either group within the observation period. These data add evidence to the notion that monitoring HIV antigen levels helps to assess the efficacy of antiviral therapy.
十名患有获得性免疫缺陷综合征的同性恋男性被纳入一项关于人类免疫缺陷病毒（HIV）抗原血症的血清学随访研究（持续时间为40周）。其中五名男性接受了逆转录酶抑制剂苏拉明治疗，为期19至37周。与报告的齐多夫定治疗后HIV抗原水平的变化相反，HIV抗原血症在苏拉明治疗组以及未治疗组中均持续存在。在观察期内，两组均未出现临床或免疫学改善。这些数据为监测HIV抗原水平有助于评估抗病毒治疗疗效这一观点增添了证据。
